A Study of DCC-2701 in Participants With Advanced Solid Tumors

• Status: Terminated
• Trial end date: 2018-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to other parts of the body.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Deciphera Pharmaceuticals LLC

Criteria

Inclusion Criteria:

• Advanced or metastatic solid tumor that has progressed or was not responsive to standard therapy

• The cancer has no proven effective therapy

• The cancer can be biopsied (depending on the tumor type and/or the dose of drug received, tumor biopsies may be required)

• Able to swallow tablets

Exclusion Criteria:

• Have active central nervous system (CNS) metastasis

• Have an active infection of any kind (fungal, viral, or bacterial)

• Are pregnant or breastfeeding